received honoraria from Celgene, Janssen, Takeda, Amgen, Abbvie.Moreau, P., Zamagni, E. & Mateos, M. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Richardson, P. G. et al. Berenson, J. R. et al. Moreau, P. et al.

These patients can have watchful waiting until signs or symptoms appear.When signs or symptoms appear, there are two categories for patients receiving treatment:Patients younger than 65 years are usually considered younger and fit. Raab, M. S. et al. Moreover, no OS data have been published to date.The most encouraging data are those achieved with the combinations of PVd or KPd, which are not approved.

This information is not intended to replace the advice of a doctor. (800) 925-4456 | For patients between the ages of 65 and 75 years, fitness is determined by their overall health and other factors.The treatment of multiple myeloma is usually done in phases: MOR202 with low-dose dexamethasone (dex) or pomalidomide/dex or lenalidomide/dex in relapsed or refractory multiple myeloma (rrmm): primary analysis of a phase i/iia, multicenter, dose-escalation study. ? Elotuzumab therapy for relapsed or refractory multiple myeloma. Bahlis, N. J. et al. Numerous large phase III trials have been performed in both the newly diagnosed and relapse/refractory disease settings in an attempt to prioritize various treatments. The combination resulted in a promising response rate and PFS (median 17.6 months for the whole group of patients)Finally, over the last few years, some trials that are being planned in the population of patients with newly diagnosed MM also include designs to evaluate rescue strategies for these patients. The treatment of multiple myeloma is usually done in phases: Induction therapy: This is the first phase of treatment. Your user session will expire in 2 minutes. The OPTIMISMM study, the last to be reported, which was intended to include patients previously exposed to lenalidomide, is closer to the real life setting and PVd therefore represents a realistic and effective combination. Multiple Myeloma (MM): Diagnosis, Treatment and Side Effects Management. As a result, patients are experiencing benefits in terms of survival and better tolerance. The results of ongoing trials using Kd or Pomalidomide-dexamethasone plus antibodies targeting CD38 are eagerly awaited.We should also encourage companies and leading authors of important trials, in which frontline therapy with lenalidomide was used either as low-dose single agent (lenalidomide maintenance after ASCTMoreau, P. et al. However, the multitude of treatment options also presents a challenge to select the best options tailored to the specific patient situation. Dimopoulos, M. A. et al. Moreau, P. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. P.M. received honoraria from Celgene, Janssen, Takeda, Amgen, Abbvie. Jakubowiak, A. et al. Know your options and determine with your care team what is right for you. Jackson, G. H. et al. Blood Cancer Journal

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Lenalidomide is increasingly being used as part of frontline therapy in newly diagnosed multiple myeloma. Palumbo, A. et al. Treatment options for multiple myeloma have grown a great deal in the past few years. The available results on approved combinations are restricted to a very low number of patients and show sub-optimal outcomes. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. Efficacy of daratumumab in combination with standard of care regimens in lenalidomide-exposed or -refractory patients with relapsed/refractory multiple myeloma (RRMM): analysis of the castor, pollux, and MMY1001 studies. Targeted therapy with a proteasome inhibitor (bortezomib). Corticosteroid therapy. You can also search for this author in